On MedTech products:
The products made and sold in the international business include many of those described above under Segments of Business – Innovative Medicine and MedTech.
JOHNSON & JOHNSON (JNJ) single-company analysis
This page is a descriptive assembly from a frozen evidence pack of public SEC filing excerpts and verified SEC companyfacts metrics. It is not a rating, recommendation, endorsement, forecast, valuation, or investment advice. Filer viewpoints are attributed to the filer and figures are as of their cited filing dates.
Informational only - not investment advice. See Disclaimer.
Back to JNJ company profile. Existing company-page SVG figures remain the source for financial time-series context.
Business & segments
Financial profile
The values below are templated from verified SEC companyfacts-derived facts. The embedded SVG figures show selected annual series from the same facts.
Reported revenue: 94,193,000,000
Net margin: 28.46%
Free cash flow: 19,698,000,000
Revenue scale is shown from verified SEC companyfacts. Revenue: 94,193,000,000
Net margin is shown from verified SEC companyfacts. Net margin: 28.46%
Free cash flow is computed from verified operating cash flow and capital expenditure facts. Free cash flow: 19,698,000,000
Capital expenditures are shown as reported payment magnitude from verified SEC companyfacts. Capital expenditures: 4,832,000,000
Share buybacks are shown as reported cash outflow magnitude from verified SEC companyfacts. Share buybacks: 5,953,000,000
| Metric | Value | Fiscal year | Period end | Source |
|---|---|---|---|---|
| Capital expenditures | 4,832,000,000 | 2025 | 2025-12-28 | USD |
| Free cash flow | 19,698,000,000 | 2025 | 2025-12-28 | USD |
| Liabilities / equity | 1.44 | 2025 | 2025-12-28 | Ratio |
| Net income | 26,804,000,000 | 2025 | 2025-12-28 | USD |
| Net margin | 28.46% | 2025 | 2025-12-28 | Percent |
| Operating cash flow | 24,530,000,000 | 2025 | 2025-12-28 | USD |
| Revenue | 94,193,000,000 | 2025 | 2025-12-28 | USD |
| Return on assets | 13.46% | 2025 | 2025-12-28 | Percent |
Stated strategy
On strategy-setting leadership:
The Executive Committee is Johnson & Johnson’s senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels.
Key idiosyncratic risks
On supply-chain exposure:
Health crises could adversely impact the Company’s operations, including, among other things, our manufacturing operations, supply chain, third-party suppliers, sales and marketing, and clinical trial operations.
On competition:
The Company faces substantial competition in its two operating segments and in all geographic markets.
Recent developments
On wholesaler concentration:
In 2025, the Company utilized three wholesalers distributing products for both segments that represented approximately 21.8%, 15.5% and 11.1% of the total gross revenues.
On immunology product sales:
Immunology products sales were $15.7 billion in 2025, a decline of 11.8% as compared to the prior year primarily due to the decline of STELARA (ustekinumab) sales driven by the impact of biosimilar competition and Medicare Part D redesign.